Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review
Open accessAbstract
Inflammation and the immune system play a role in the development and progression of melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). The pro-inflammatory and tumor-promoting effects of the high-mobility group box-1 (HMGB1) protein and the receptor for advanced glycation end products (RAGE) have been investigated in these cutaneous malignancies. The clinical implication of these molecules is not fully described. The National Library of Medicine database was searched for articles addressing the clinical relevance of HMGB1 and RAGE in melanoma, BCC, and SCC. This systematic review includes nine articles, with six summarizing RAGE in cutaneous malignancies and three involving HMGB1. RAGE has been found to be up-regulated in SCC lesions, as well as melanoma. Levels of RAGE were highest in stage IV melanomas. Lower levels of soluble RAGE have been associated with poor overall survival in melanoma. Sporadic extracellular expression of HMGB1 was evident in BCC and SCC lesions, which could be released by necrotic tumor cells. HMGB1 was found to be a prognostic marker in melanoma, and HMGB1 levels were elevated in patients who were non-responders to ipilimumab treatment. HMGB1 and RAGE could serve as potential prognostic markers or therapeutic targets in treating melanoma, BCC, and SCC, but further research regarding the clinical utility of the HMGB1-RAGE axis in cutaneous malignancies is warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In hepatocellular carcinoma, RAGE overexpression and interaction with HMGB1 induce tumor-associated macrophage activation and NF-κB expression to promote tumoral proliferation, invasion, and metastasis.
“In hepatocellular carcinoma (HCC), RAGE overexpression and interaction with HMGB1 induce tumor-associated macrophage activation and NF-κB expression to promote tumoral proliferation, invasion, and metastasis90,91.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1782 · Cited by 2,261 · see citing works
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436 · see citing works
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217 · see citing works
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956 · see citing works
Sparvero, L. J., Asafu-Adjei, D. A., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 625 · see citing works
HMGB1 in Cancer: Good, Bad, or Both?
Kang, R., Zhang, Q., Zeh, H. J., Lotze, M. T., & Tang, D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0495 · Cited by 496 · see citing works
Binding of S100 proteins to RAGE: An update
Leclerc, E., Fritz, G., Vetter, S. W., & Heizmann, C. W. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.016 · Cited by 490 · see citing works
High-Mobility Group Box 1, Oxidative Stress, and Disease
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3356 · Cited by 465 · see citing works
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0786 · Cited by 434 · see citing works
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367 · see citing works
Toll-like receptors in inflammation, infection and cancer
Chen, K., Huang, J., Gong, W., Iribarren, P., Dunlop, N. M., & Wang, J. M. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.05.016 · Cited by 324 · see citing works
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · see citing works
RAGE and RAGE ligands in cancer
Logsdon, C., Fuentes, M., Huang, E., & Arumugam, T. (2007) · Current Molecular Medicine · doi:10.2174/156652407783220697 · Cited by 209 · see citing works
Skin Cancer Epidemiology, Detection, and Management
Gandhi, S. A., & Kampp, J. T. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.06.002 · Cited by 179 · see citing works
Regulation of Human Melanoma Growth and Metastasis by AGE–AGE Receptor Interactions
Abe, R., Shimizu, T., Sugawara, H., Watanabe, H., Nakamura, H., Choei, H., Sasaki, N., Yamagishi, S., Shimizu, H., & Takeuchi, M. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22218.x · Cited by 145 · see citing works
Poser, I., Golob, M., Buettner, R., & Bosserhoff, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2991-2998.2003 · Cited by 110 · see citing works
The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines
Chen, R.-C., Yi, P.-P., Zhou, R.-R., Xiao, M.-F., Huang, Z.-B., Tang, D., Huang, Y., & Fan, X. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-1978-6 · Cited by 109 · see citing works
Malik, P., Chaudhry, N., Mittal, R., & Mukherjee, T. K. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.05.020 · Cited by 88 · see citing works
HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism
Armando Rojas, R., Delgado‐López, F., Pérez-Castro, R., González, I., Romero, J. A., Rojas, I., Araya, P., Añazco, C. C., Morales, E., & Jorge Llanos, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3940-y · Cited by 82 · see citing works
Li, Q., Li, J., Wen, T., Zeng, W., Peng, C., Yan, S., Tan, J., Yang, K., Liu, S., Guo, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2201 · Cited by 57 · see citing works
Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy
Yanofsky, V. R., Mitsui, H., Felsen, D., & Carucci, J. A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/624123 · Cited by 52 · see citing works
Todorova, J., & Pasheva, E. A. (2011) · Oncology Letters · doi:10.3892/ol.2011.459 · Cited by 51 · see citing works
Sharma, A. K., Ray, R., & Rajeswari, M. R. (2008) · Cancer Investigation · doi:10.1080/07357900801954210 · Cited by 51 · see citing works
The Immune System and Skin Cancer
Yu, S. H., Bordeaux, J. S., & Baron, E. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0437-2_10 · Cited by 50 · see citing works
RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells
Leclerc, E., Heizmann, C. W., & Vetter, S. W. (2009) · PubMed · doi:10.5167/uzh-26499 · Cited by 48 · see citing works
mRNA expression of tumor‐associated antigens in melanoma tissues and cell lines
Eichmüller, S. B., Usener, D., Jochim, A., et al. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110402.x · Cited by 44 · see citing works
Do inflammatory pathways drive melanomagenesis?
Schneider, S. L., Ross, A. L., & Grichnik, J. M. (2014) · Experimental Dermatology · doi:10.1111/exd.12502 · Cited by 35 · see citing works
Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma
Zhu, L., Ito, T., Nakahara, T., et al. (2013) · The Journal of Dermatology · doi:10.1111/1346-8138.12323 · Cited by 32 · see citing works
Sharma, A. K., Allam, R., Ray, R., & Rajeswari, M. R. (2009) · DNA and Cell Biology · doi:10.1089/dna.2009.0851 · Cited by 16 · see citing works
Introduction to the role of the immune system in melanoma.
Margolin, K. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.005 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Nguyen A, Bhavsar S, Riley E, Caponetti G and Agrawal D: Clinical value of high mobility group box 1 and the receptor for advanced glycation endproducs in head and neck cancer: A systematic review. Int Arch Otorhinolaryngol 20: 382-389, 2016.
Cited by
Sorted by citations
Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M., & Song, B.-J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00561-7 · Cited by 411 · see citing works
Role of advanced glycation end products in carcinogenesis and their therapeutic implications
Schröter, D., & Höhn, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130145549 · Cited by 126 · see citing works
- Authors
- NGUYEN, A. H., DETTY, S. Q., & AGRAWAL, D. K.
- Affiliations
- Creighton University (US)
- Venue
- Anticancer Research
- Published
- 2017-01-01
- Volume
- 37
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0250-7005 (ISSN-L)
- 1791-7530
- OpenAlex
- W2566717269
- Cited by
- 48
- References
- 30
- Citations by year
- 2026: 3 · 2024: 5 · 2023: 1 · 2022: 4 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 10 · 2017: 5 · 2016: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Anticancer Research (publishedVersion)
- PubMed (publishedVersion)
- Creighton Digital Repository (CDR) (submittedVersion)
- Funders
- Creighton University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Keywords
- HMGB1, RAGE, advanced glycation end products, melanoma, basal cell carcinoma, squamous cell carcinoma, skin cancer, prognostic factors, therapeutic target, inflammation, overall survival
- MeSH terms
- Receptor for Advanced Glycation End Products, Animals, Basal Cell Carcinoma, Carcinoma, Squamous Cell, Cell Transformation, Neoplastic, Humans, Melanoma, Predictive Value of Tests, Prognosis, Risk Factors, Skin Neoplasms, Biomarkers, Tumor, Signal Transduction, Inflammation Mediators, HMGB1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
